{"id":56183,"date":"2026-02-03T22:03:34","date_gmt":"2026-02-03T14:03:34","guid":{"rendered":"https:\/\/flcube.com\/?p=56183"},"modified":"2026-02-03T22:03:35","modified_gmt":"2026-02-03T14:03:35","slug":"jumpcan-licenses-primegenx-pumecitinib-nasal-spray-for-allergic-rhinitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56183","title":{"rendered":"Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis"},"content":{"rendered":"\n<p><strong>Jumpcan Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600566:SHA\">SHA: 600566<\/a>) announced a partnership with <strong>PrimeGenX Therapeutics Co., Ltd.<\/strong> granting Jumpcan exclusive commercialization rights to <strong>pumecitinib nasal spray (G\u2011011)<\/strong> in <strong>Greater China<\/strong> (mainland China, Hong Kong, Macau, and Taiwan). The deal includes up to <strong>RMB\u202f100\u202fmillion<\/strong> (USD\u202f14.4\u202fmillion) in consideration and a double\u2011digit promotion service fee post\u2011launch.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-strategic-terms\">Deal Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>PrimeGenX Therapeutics Co., Ltd.<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Jumpcan Pharmaceutical (600566.SH)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Pumecitinib nasal spray (G\u2011011)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Allergic rhinitis<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Greater China (exclusive)<\/td><\/tr><tr><td><strong>Consideration<\/strong><\/td><td>RMB\u202f100\u202fmillion (RMB\u202f40\u202fM upfront + RMB\u202f60\u202fM milestone)<\/td><\/tr><tr><td><strong>Promotion Fee<\/strong><\/td><td>Double\u2011digit sales\u2011based service fee post\u2011launch<\/td><\/tr><tr><td><strong>Clinical Status<\/strong><\/td><td>Phase\u202fIII clinical study; trial nod in China (August\u202f2023)<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>Potential world\u2019s first JAK inhibitor nasal spray<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-clinical-development\">Drug Profile &amp; Clinical Development<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>JAK1\/2 inhibitor<\/strong> targeting inflammatory pathways in allergic rhinitis<\/li>\n\n\n\n<li><strong>Formulation:<\/strong> Nasal spray delivery offers localized treatment with reduced systemic exposure<\/li>\n\n\n\n<li><strong>Development:<\/strong> Phase\u202fIII trial underway following Chinese regulatory approval in August\u202f2023<\/li>\n\n\n\n<li><strong>Market Need:<\/strong> Allergic rhinitis affects <strong>~250\u202fmillion<\/strong> : patients in China; limited options beyond antihistamines and intranasal steroids<\/li>\n\n\n\n<li><strong>First\u2011in\u2011Class Potential:<\/strong> If approved, would be the <strong>first JAK inhibitor nasal spray<\/strong> globally<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Allergic Rhinitis Market:<\/strong> Valued at <strong>\u00a515\u202fbillion<\/strong> : (~US$2.1\u202fbillion) in 2025, growing at <strong>10% CAGR<\/strong> :<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a5500\u2013800\u202fmillion<\/strong> : (US$70\u2013112\u202fmillion) peak annual sales if pumecitinib captures 5\u20138% of moderate\u2011to\u2011severe patient segment<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Partnership combines PrimeGenX\u2019s innovation with Jumpcan\u2019s commercial reach; double\u2011digit promotion fee aligns incentives for successful launch<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes with <strong>fluticasone, mometasone<\/strong> steroids and <strong>azelastine<\/strong> antihistamines; JAK inhibition offers novel mechanism for refractory patients<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Phase\u202fIII data readout expected <strong>Q3\u202f2026<\/strong>; NDA submission targeted for <strong>H1\u202f2027<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for pumecitinib nasal spray. Actual results may differ due to clinical trial outcomes, competitive dynamics, and NMPA review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/600566_20260203_1GAH.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600566_20260203_1GAH.\"><\/object><a id=\"wp-block-file--media-dce4ab08-6fc7-44c2-853b-054672a4bb57\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/600566_20260203_1GAH.pdf\">600566_20260203_1GAH<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/600566_20260203_1GAH.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-dce4ab08-6fc7-44c2-853b-054672a4bb57\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2418,4588,2419],"class_list":["post-56183","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-jumpcan-pharmaceutical","tag-primegenx-therapeutics","tag-sha-600566"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive commercialization rights to pumecitinib nasal spray (G\u2011011) in Greater China (mainland China, Hong Kong, Macau, and Taiwan). The deal includes up to RMB\u202f100\u202fmillion (USD\u202f14.4\u202fmillion) in consideration and a double\u2011digit promotion service fee post\u2011launch.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56183\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis\" \/>\n<meta property=\"og:description\" content=\"Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive commercialization rights to pumecitinib nasal spray (G\u2011011) in Greater China (mainland China, Hong Kong, Macau, and Taiwan). The deal includes up to RMB\u202f100\u202fmillion (USD\u202f14.4\u202fmillion) in consideration and a double\u2011digit promotion service fee post\u2011launch.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56183\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T14:03:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T14:03:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56183#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56183\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis\",\"datePublished\":\"2026-02-03T14:03:34+00:00\",\"dateModified\":\"2026-02-03T14:03:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56183\"},\"wordCount\":326,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Jumpcan Pharmaceutical\",\"PrimeGenX Therapeutics\",\"SHA: 600566\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56183#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56183\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56183\",\"name\":\"Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-03T14:03:34+00:00\",\"dateModified\":\"2026-02-03T14:03:35+00:00\",\"description\":\"Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive commercialization rights to pumecitinib nasal spray (G\u2011011) in Greater China (mainland China, Hong Kong, Macau, and Taiwan). The deal includes up to RMB\u202f100\u202fmillion (USD\u202f14.4\u202fmillion) in consideration and a double\u2011digit promotion service fee post\u2011launch.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56183#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56183\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56183#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis - Insight, China&#039;s Pharmaceutical Industry","description":"Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive commercialization rights to pumecitinib nasal spray (G\u2011011) in Greater China (mainland China, Hong Kong, Macau, and Taiwan). The deal includes up to RMB\u202f100\u202fmillion (USD\u202f14.4\u202fmillion) in consideration and a double\u2011digit promotion service fee post\u2011launch.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56183","og_locale":"en_US","og_type":"article","og_title":"Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis","og_description":"Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive commercialization rights to pumecitinib nasal spray (G\u2011011) in Greater China (mainland China, Hong Kong, Macau, and Taiwan). The deal includes up to RMB\u202f100\u202fmillion (USD\u202f14.4\u202fmillion) in consideration and a double\u2011digit promotion service fee post\u2011launch.","og_url":"https:\/\/flcube.com\/?p=56183","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-03T14:03:34+00:00","article_modified_time":"2026-02-03T14:03:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56183#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56183"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis","datePublished":"2026-02-03T14:03:34+00:00","dateModified":"2026-02-03T14:03:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56183"},"wordCount":326,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Jumpcan Pharmaceutical","PrimeGenX Therapeutics","SHA: 600566"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56183#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56183","url":"https:\/\/flcube.com\/?p=56183","name":"Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-03T14:03:34+00:00","dateModified":"2026-02-03T14:03:35+00:00","description":"Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive commercialization rights to pumecitinib nasal spray (G\u2011011) in Greater China (mainland China, Hong Kong, Macau, and Taiwan). The deal includes up to RMB\u202f100\u202fmillion (USD\u202f14.4\u202fmillion) in consideration and a double\u2011digit promotion service fee post\u2011launch.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56183#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56183"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56183#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56183","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56183"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56183\/revisions"}],"predecessor-version":[{"id":56187,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56183\/revisions\/56187"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56183"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56183"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}